- Market Capitalization, $K 578,659
- Shares Outstanding, K 28,186
- Annual Sales, $ 63,180 K
- Annual Income, $ -57,800 K
- 60-Month Beta 0.17
- Price/Sales 9.32
- Price/Cash Flow N/A
- Price/Book 1.75
|Period||Period Low||Period High||Performance|
| || |
-4.29 (-18.27%)since 04/25/22
| || |
-12.24 (-38.94%)since 02/25/22
| || |
-4.81 (-20.04%)since 05/25/21
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and...
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term....
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs ...
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue...
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing...
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for...
|3rd Resistance Point||21.08|
|2nd Resistance Point||20.62|
|1st Resistance Point||19.90|
|1st Support Level||18.72|
|2nd Support Level||18.26|
|3rd Support Level||17.54|